Aummune Overview
- Founded
- 2017
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Investors
- 1
Aummune General Information
Description
Developer of cancer therapeutics intended to provide personalized patient-specific disease parameters at each stage of the therapeutic pathway. The company's therapeutics addresses the unmet need for highly personalized, targeted, safe and agile therapies for widespread, life-threatening diseases, enabling cancer patients to transform their lives through therapeutics by revolutionising the way in which cancer, antibiotic-resistant bacteria and viruses are treated medically.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Tel Aviv Medical Center (TAMC)
- Sammy Ofer Building - Floor 10, 6 Weizmann Street
- Tel Aviv
- Israel
Aummune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Jan-2017 | Completed | Startup |
Aummune Executive Team (5)
Aummune Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Yair Schindel MD | aMoon Fund | Chairman | 000 0000 |
Aummune Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| aMoon Fund | Venture Capital | Minority | 000 0000 | 000000 0 |